Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering’s largest shareholder accepts Bayer takeover offer
Bayer previously extended the timeframe on its E86 cash per share offer for Schering by an extra two weeks in order to allow it extra time to acquire
Bayer previously extended the timeframe on its E86 cash per share offer for Schering by an extra two weeks in order to allow it extra time to acquire
Preliminary results from the phase I hematology study are published in the 2006 American Society of Clinical Oncology annual meeting proceedings. An anti-leukemia effect was seen in two
As a result, Akzo Nobel has decided not to launch the drug in the US and has accordingly withdrawn its application with the FDA. The decision by the
Doxycycline is indicated for a variety of infections when caused by susceptible strains of microorganisms, including respiratory tract and urinary tract infections, skin and skin structure infections, and
Although the trial met its primary efficacy endpoint, the results are disappointing in the context of pivotal trials of Lucentis in monthly dosing regimens that have shown the
Li-Fraumeni syndrome (LFS) is a genetic disorder characterized by inherited mutations in the p53 tumor suppressor gene. This abnormal p53 function is directly addressed by Advexin treatment. “In
Atryn may be given in association with heparin or low molecular weight heparin in these situations. The positive opinion of the advisory board recommends granting market authorization under
The Committee for Medicinal Products for Human Use’s (CHMP’s) positive opinion will now be considered by the European Commission, which is expected to issue a final decision regarding
In July 2005 the FDA issued an approvable letter for Entereg, an investigational drug under review for the management of postoperative ileus (POI) by acceleration of the time
Bristol-Myers Squibb (BMS) will provide Lexicon $20 million in additional research funding over the two-year extended research term which begins in January 2007. The drug target discovery portion